No abstract

PurposeThe purpose of this study is to define if tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) could represent potential predictors of lymph node metastases (LNM) in salivary gland cancers (SGC).MethodsA selected number of immunohistochemical markers related to TILs (CD3, CD4, CD68, and FOXP3) and TAMs (CD68 and CD163) were investigated on major salivary gland cancers. TIL and TAM densities were measured on digital images using the open-source QuPath both in the tumor interior (TI) and invasive margin (IM). Correlation with pathologic N classification and follow-up clinical data was investigated.ResultsA total of 25 consecutive patients (men: 11; median age: 62.0) were included. Densities of CD3+ IM (OR = 7.7, 95% CI 1.2–51.2), CD8+ TI (OR = 7.7, 95% CI 1.2–51.2), CD8+ IM (OR = 7.7, 95% CI 1.2–51.2), FOXP3+ TI (OR = 24.0, 95% CI 2.2–255.9), CD68+ TI (OR = 7.7, 95% CI 1.2–51.2), and CD163+ IM (OR = 7.7, 95% CI 1.2 – 51.2), and the Immunoscore CD8/CD3 (OR = 1.9, 95% CI 1.1–3.4) were significantly associated with LNM (p < 0.05). CD3+ TI density was significantly associated with tumor recurrence and death (HR = 5.8, 95% CI 1.5–22.6; p < 0.05).ConclusionA high density of specific TIL and TAM subpopulations might be correlated with a higher probability of LNM in SGC.

Objective To determine the oncological outcomes of salvage transoral laser microsurgery (TLM) in the treatment of patients suffering from recurrent laryngeal cancer. Methods PubMed/MEDLINE, Cochrane Library, and Scopus databases were searched. English language, original studies investigating oncological outcomes of TLM in adult patients with recurrent laryngeal cancer were included. Data were pooled using a distribution‐free approach for estimating summary local control (LC), disease‐specific survival (DSS), and overall survival (OS) curves with random effects. Results Two hundred and thirty‐five patients underwent salvage TLM after primary (chemo)radiotherapy. The mean follow‐up time was 60.8 months (95% CI: 32.7–88.9). Estimated pooled LC rates (95% CI) at 1, 3 and 5 years were 74.2% (61.7–89.4), 53.9% (38.5–75.3), and 39.1% (25.2–60.8). Estimated pooled DSS rates (95% CI) at 1, 3 and 5 years were 88.4% (82.0–95.3), 67.8% (50.9–90.3), and 58.9% (42.7–81.1). Two hundred and seventy‐one patients underwent TLM after primary laser treatment. The mean follow‐up time was 70.9 months (95% CI: 36.9–104.9). Estimated pooled LC rates (95% CI) at 1, 3 and 5 years were 72.2% (64.7–80.6), 53.2% (42.2–66.9), and 40.4% (29.6–55.2). Estimated pooled DSS rates (95% CI) at 1, 3 and 5 years were 92.1% (85.5–99.1), 77.0% (64.4–92.0), and 67.1% (51.6–87.3). Conclusions TLM is a valuable treatment option for the management of locally recurrent laryngeal carcinoma if performed by experienced surgeons and following rigorous patients' selection criteria. Further studies should be conducted to define stage‐based clinical guidelines. Level of Evidence NA Laryngoscope, 133:1425–1433, 2023